- Conditions
- Lung Transplant, CMV
- Interventions
- Letermovir, Valganciclovir
- Drug
- Lead sponsor
- Fernanda P Silveira, MD, MS
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–8
of 8
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HCMV Reactivation or HCMV End-Organ Disease
- Interventions
- 60 mg AIC246, 120 mg AIC246, 240 mg AIC246, Placebo
- Drug · Other
- Lead sponsor
- AiCuris Anti-infective Cures AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 133 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Stanford, California • Denver, Colorado + 11 more
- Conditions
- Cytomegalovirus (CMV) Infection
- Interventions
- Letermovir oral granules, Letermovir tablet, Letermovir intravenous
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 11
- States / cities
- Duarte, California • Orange, California • San Francisco, California + 8 more
- Conditions
- HIV Infections, Cytomegalovirus, CMV
- Interventions
- Letermovir Oral Tablet
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 40 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 15
- States / cities
- San Diego, California • San Francisco, California • Aurora, Colorado + 11 more
- Conditions
- Cytomegalovirus Prophylaxis
- Interventions
- Letermovir
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 17 more
- Conditions
- CMV Disease
- Interventions
- Letermovir, Valganciclovir, Acyclovir (ACV), Placebo to ACV, Placebo to LET, Placebo to VGCV
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 601 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 21 more
- Conditions
- Cytomegalovirus Infection
- Interventions
- Letermovir, Placebo
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 10
- States / cities
- Duarte, California • Sacramento, California • Miami, Florida + 7 more
- Conditions
- Kidney Transplant, Liver Transplant
- Interventions
- Letermovir
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin